Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology
S Bergan, M Brunet, DA Hesselink… - Therapeutic drug …, 2021 - journals.lww.com
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …
Pharmacogenetics and immunosuppressive drugs in solid organ transplantation
T Van Gelder, RH Van Schaik… - Nature Reviews …, 2014 - nature.com
The transplantation literature includes numerous papers that report associations between
polymorphisms in genes encoding metabolizing enzymes and drug transporters, and …
polymorphisms in genes encoding metabolizing enzymes and drug transporters, and …
Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population
W Zhao, H Meng - Bioengineered, 2022 - Taylor & Francis
As a chronic brain disease, epilepsy affects~ 50 million people worldwide. The traditional
antiepileptic drugs (AEDs) are widely applied but showing various problems. Although the …
antiepileptic drugs (AEDs) are widely applied but showing various problems. Although the …
PharmGKB summary: mycophenolic acid pathway
V Lamba, K Sangkuhl, K Sanghavi, A Fish… - Pharmacogenetics …, 2014 - journals.lww.com
Mycophenolic acid (MPA) is an immunosuppressive agent available either as an ester
prodrug or as a sodium salt. Mycophenolate mofetil (MMF) is the 2-morpholinoethyl ester …
prodrug or as a sodium salt. Mycophenolate mofetil (MMF) is the 2-morpholinoethyl ester …
The impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of mycophenolic acid: systematic review and meta-analysis
M Na Takuathung, W Sakuludomkan… - Clinical …, 2021 - Springer
Background Mycophenolic acid (MPA) is among the most commonly prescribed medications
for immunosuppression following organ transplantation. Highly variable MPA exposure and …
for immunosuppression following organ transplantation. Highly variable MPA exposure and …
Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients
Z Yu, P Zhou, X Wang, B Françoise, D Xu… - Acta pharmacologica …, 2017 - nature.com
Mycophenolate mofetil (MMF) is an important immunosuppressant used in renal
transplantation, and mycophenolic acid (MPA) is the active component released from the …
transplantation, and mycophenolic acid (MPA) is the active component released from the …
[PDF][PDF] Liver diseases in the perinatal period: interactions between mother and infant
SH Ibrahim, MM Jonas, SA Taylor… - …, 2020 - Wiley Online Library
Liver diseases affecting the mother and infant dyad may present in the perinatal period from
20 weeks of gestation to 28 days of life. This review will focus on the current approach to …
20 weeks of gestation to 28 days of life. This review will focus on the current approach to …
Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?
P Li, N Shuker, DA Hesselink… - Transplant …, 2014 - Wiley Online Library
Mycophenolate mofetil (MMF) is used to prevent acute rejection following solid organ
transplantation in transplant centers all over the world. Patients from different ethnic …
transplantation in transplant centers all over the world. Patients from different ethnic …
Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co‐treated …
C Yang, C Sheng, G Liao, Y Su, L Feng… - Journal of Clinical …, 2021 - Wiley Online Library
What is known and objective Mycophenolate mofetil, an ester prodrug of mycophenolic acid
(MPA), is widely used to prevent graft rejection after kidney transplantation. The …
(MPA), is widely used to prevent graft rejection after kidney transplantation. The …
Pharmacogenomics of Old and New Immunosuppressive Drugs for Precision Medicine in Kidney Transplantation
S Turolo, A Edefonti, ML Syren, G Montini - Journal of Clinical Medicine, 2023 - mdpi.com
Kidney transplantation is the preferred therapeutic option for end-stage kidney disease, but,
despite major therapeutic advancements, allograft rejection continues to endanger graft …
despite major therapeutic advancements, allograft rejection continues to endanger graft …